10/2/2020 11:45:44 AM
Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split
9/14/2020 4:36:31 PM
Novus Therapeutics Announces Acquisition Of Anelixis Therapeutics
4/22/2019 8:10:56 AM
Novus Therapeutics Announces Results Of Two Single-Dose OP0201 Phase 1 Clinical Trials
2/11/2019 8:07:24 AM
Novus Doses First Subjects In Phase 1 Pharmacodynamics Study Of OP0201
1/30/2019 8:07:35 AM
Novus Therapeutics Provides Updates On Several Ongoing And Planned Clinical Trials With OP0201
1/8/2019 8:06:20 AM
Novus Therapeutics Doses First Adult Patient With Acute Otitis Media In Phase 1 Clinical Trial Of OP0201
12/4/2018 8:13:06 AM
Novus Therapeutics Says Forms Scientific Advisory Board To Work Closely With The Novus Mgmt. Team To Advance OP0201
11/13/2018 8:20:23 AM
Novus Therapeutics Q3 Net Loss $3.5 Mln Or $0.37/shr Vs. Net Loss $3.0 Mln Or $0.43/shr Last Year
9/7/2018 9:27:39 AM
Novus Therapeutics To Postpone Public Offering Of Common Stock Due To Market Conditions
9/4/2018 4:08:27 PM
Novus Therapeutics Announces Proposed Public Offering Of Common Stock
8/7/2018 8:36:59 AM
Novus Therapeutics Q2 Net Loss $3.2 Mln Or $0.34/Shr Vs Loss Of $6.7 Mln Or $1.32/Shr Last Year
6/19/2018 7:34:29 AM
Novus Therapeutics Gets FDA Guidance At Type C Meeting For OP-02 In The Treatment And Prevention Of Otitis Media